Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (401)	4/9/1999 11:50:00 PM
From: aknahow	Read Replies (1) \| Respond to of 712

Have no idea. What does the company accomplish by keeping this information so tight? If sales are poor, I could understand concealment. In the meantime here is the URL for the ECS. Many links to journals and meetings. esc.be

To: LLCF who wrote (401)	4/11/1999 11:43:00 AM
From: Anaxagoras	Respond to of 712

<<Any estimate for 1999 on Intergrelin saless???????????>> No; but as a general starting place we have this from the recently filed 10-K: <<Total sales of INTEGRILIN to wholesalers, as reported to the Company by Schering, were $12,200,000 from launch in June 1998 through December 31, 1998.>> This is also useful: <<COR believes that INTEGRILIN sales will increase as early usage becomes more common and as the number of hospitals stocking INTEGRILIN increases. COR and Schering have identified over 2,000 hospitals as initial potential users of INTEGRILIN. Over 1,100 of these hospitals currently stock or use INTEGRILIN.>> Anaxagoras